0001176407-13-000005.txt : 20130911
0001176407-13-000005.hdr.sgml : 20130911
20130911113234
ACCESSION NUMBER: 0001176407-13-000005
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: Rule 506
FILED AS OF DATE: 20130911
DATE AS OF CHANGE: 20130911
EFFECTIVENESS DATE: 20130911
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: INTRA CELLULAR THERAPIES INC
CENTRAL INDEX KEY: 0001176407
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-202684
FILM NUMBER: 131090429
BUSINESS ADDRESS:
STREET 1: AUDUBON BIOMEDICAL SCIENCE
STREET 2: & TECHNOLOGY PARK, 3960 BROADWAY
CITY: NEW YORK
STATE: NY
ZIP: 10032
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: AUDUBON BIOMEDICAL SCIENCE
STREET 2: & TECHNOLOGY PARK, 3960 BROADWAY
CITY: NEW YORK
STATE: NY
ZIP: 10032
D
1
primary_doc.xml
X0706
D
LIVE
0001176407
INTRA CELLULAR THERAPIES INC
AUDUBON BIOMEDICAL SCIENCE
& TECHNOLOGY PARK, 3960 BROADWAY
NEW YORK
NY
NEW YORK
10032
212-923-3344
DELAWARE
None
None
Corporation
true
Sharon
Mates
3960 Broadway
New York
NY
NEW YORK
10032
Executive Officer
Director
Allen
Fienberg
3960 Broadway
New York
NY
NEW YORK
10032
Executive Officer
Lawrence
Wennogle
3960 Broadway
New York
NY
NEW YORK
10032
Executive Officer
Lawrence
Hineline
3960 Broadway
New York
NY
NEW YORK
10032
Executive Officer
Kimberly
Vanover
3960 Broadway
New York
NY
NEW YORK
10032
Executive Officer
Christopher
Alafi
3960 Broadway
New York
NY
NEW YORK
10032
Director
Richard
Lerner
3960 Broadway
New York
NY
NEW YORK
10032
Director
Joel
Marcus
3960 Broadway
New York
NY
NEW YORK
10032
Director
Michael
Rawlins
3960 Broadway
New York
NY
NEW YORK
10032
Director
Biotechnology
Decline to Disclose
- 06
false
2013-08-29
false
true
true
Reverse Merger will take place after offering.
0
Leerink Swann LLC
39011
None
None
1 Federal Street
Boston
MA
MASSACHUSETTS
02110
AZ
ARIZONA
CA
CALIFORNIA
DC
DISTRICT OF COLUMBIA
MA
MASSACHUSETTS
MO
MISSOURI
NJ
NEW JERSEY
NY
NEW YORK
false
National Securities Corporation
7569
None
None
120 Broadway
New York
NY
NEW YORK
10271
AL
ALABAMA
AZ
ARIZONA
CA
CALIFORNIA
CO
COLORADO
CT
CONNECTICUT
FL
FLORIDA
GA
GEORGIA
IL
ILLINOIS
IN
INDIANA
LA
LOUISIANA
MD
MARYLAND
MA
MASSACHUSETTS
MN
MINNESOTA
NH
NEW HAMPSHIRE
NJ
NEW JERSEY
NY
NEW YORK
OK
OKLAHOMA
OR
OREGON
PA
PENNSYLVANIA
TX
TEXAS
UT
UTAH
VA
VIRGINIA
WA
WASHINGTON
WI
WISCONSIN
false
Livingston Securities, LLC
147364
None
None
825 Third Avenue
New York
NY
NEW YORK
10022
AL
ALABAMA
AR
ARKANSAS
CA
CALIFORNIA
CO
COLORADO
CT
CONNECTICUT
DE
DELAWARE
FL
FLORIDA
GA
GEORGIA
IL
ILLINOIS
LA
LOUISIANA
MD
MARYLAND
MA
MASSACHUSETTS
MI
MICHIGAN
MN
MINNESOTA
MS
MISSISSIPPI
NJ
NEW JERSEY
NY
NEW YORK
OH
OHIO
OR
OREGON
PA
PENNSYLVANIA
TN
TENNESSEE
TX
TEXAS
VA
VIRGINIA
WA
WASHINGTON
WY
WYOMING
false
60000000
60000000
0
Includes approximately $15.3 million in principal, plus accrued interest, from the conversion of outstanding convertible notes.
false
185
2905000
true
0
Will be paid in aggregate cash fee not to exceed $2,905,000.
0
false
INTRA CELLULAR THERAPIES INC
/s/ Sharon Mates
Sharon Mates
Founder, Chairman, President and Chief Executive Officer
2013-09-11